Key Points
- Insider Thomas Hogan sold 25,299 Cellebrite DI shares at an average price of $11.29, receiving approximately $285,626. He retained 765,249 shares after the transaction, a 3.2% reduction in his ownership.
- Cellebrite DI shares opened at $12.29, with the company valued at approximately $3.07 billion. The stock has traded between $9.58 and $19.98 over the past year, while institutional investors and hedge funds own 45.88% of outstanding shares.
- Analysts lowered their price targets but generally remained positive: five analysts rate the stock a Buy and one rates it a Sell. The consensus rating is Moderate Buy, with an average price target of $16.70.
Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) insider Thomas Hogan sold 25,299 shares of the business's stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $11.29, for a total value of $285,625.71. Following the sale, the insider directly owned 765,249 shares of the company's stock, valued at $8,639,661.21. This represents a 3.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Cellebrite DI Trading Up 5.8%
Cellebrite DI stock opened at $12.29 on Friday. The company has a market cap of $3.07 billion, a PE ratio of 55.87, a PEG ratio of 1.78 and a beta of 1.18. Cellebrite DI Ltd. has a 1 year low of $9.58 and a 1 year high of $19.98. The company's 50-day moving average is $14.18 and its two-hundred day moving average is $13.79.
Institutional Trading of Cellebrite DI
Hedge funds have recently modified their holdings of the company. Roubaix Capital LLC increased its stake in Cellebrite DI by 108.1% in the first quarter. Roubaix Capital LLC now owns 303,215 shares of the company's stock valued at $4,178,000 after purchasing an additional 157,536 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in Cellebrite DI in the first quarter worth $2,134,000. Principal Financial Group Inc. boosted its position in shares of Cellebrite DI by 33.9% during the first quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company's stock worth $29,712,000 after purchasing an additional 545,334 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Cellebrite DI by 14.7% during the first quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company's stock worth $39,420,000 after purchasing an additional 365,700 shares in the last quarter. Finally, Weiss Asset Management LP grew its holdings in shares of Cellebrite DI by 3,485.3% in the 1st quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company's stock valued at $26,180,000 after buying an additional 1,846,851 shares during the period. 45.88% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several brokerages recently weighed in on CLBT. Lake Street Capital cut their price objective on shares of Cellebrite DI from $21.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, August 14th. DA Davidson lowered their target price on shares of Cellebrite DI from $22.00 to $15.00 and set a "buy" rating for the company in a report on Friday, August 14th. Needham & Company LLC dropped their target price on shares of Cellebrite DI from $15.00 to $12.50 and set a "buy" rating for the company in a research report on Friday, August 14th. Weiss Ratings downgraded Cellebrite DI from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Thursday, August 13th. Finally, JPMorgan Chase & Co. reduced their price target on Cellebrite DI from $20.00 to $16.00 and set an "overweight" rating on the stock in a research report on Friday, August 14th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Cellebrite DI currently has an average rating of "Moderate Buy" and a consensus target price of $16.70.
Read Our Latest Stock Analysis on CLBT
About Cellebrite DI
(
Get Free Report)
Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.
The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
